Studies of incidence of systemic/CNS or CNS-only ARL before and after HAART
. | . | Cases by HAART . | . | Relative risk of systemic ARL before vs after HAART . | Relative risk of CNS ARL before vs after HAART . | |
|---|---|---|---|---|---|---|
| Reference . | Type and comments . | Before . | After . | . | . | |
| Grulich et al5 | Before HAART: 1990-94, 7.0 cases/1000 p-y, 94-96, 7.5; after HAART: 4.3, 96-98 | 190 | 23 | 0.6, P < .012 | NR | |
| Kirk et al6 | Immunoblastic NHL 5-fold/Burkitt 6-fold decreased risk since HAART | 125 | 97 | 0.44, P < .001 | 0.05 | |
| Besson et al7 | French Hospital Database on HIV | 415 | 285 | 0.50 (systemic only), P < .001 | 0.35, P < .001 | |
. | . | Cases by HAART . | . | Relative risk of systemic ARL before vs after HAART . | Relative risk of CNS ARL before vs after HAART . | |
|---|---|---|---|---|---|---|
| Reference . | Type and comments . | Before . | After . | . | . | |
| Grulich et al5 | Before HAART: 1990-94, 7.0 cases/1000 p-y, 94-96, 7.5; after HAART: 4.3, 96-98 | 190 | 23 | 0.6, P < .012 | NR | |
| Kirk et al6 | Immunoblastic NHL 5-fold/Burkitt 6-fold decreased risk since HAART | 125 | 97 | 0.44, P < .001 | 0.05 | |
| Besson et al7 | French Hospital Database on HIV | 415 | 285 | 0.50 (systemic only), P < .001 | 0.35, P < .001 | |
p-y indicates patient-years; NR, not reported.